Stem cell-based treatments for gynecological solid tumors

European Review for Medical and Pharmacological Sciences

Volumn 9, Issue 2, 2005, Pages 93-102

  Perillo, A ^c   Ferrandina, G ^c   Pierelli, L ^a   Bonanno, G ^c   Scambia, G ^b   Mancuso, S ^c  

^a ASL Viterbo   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Gynecological tumors; Progenitor cell transplantation; Stem cells

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; DENDRITIC CELL VACCINE; EPIRUBICIN; ERYTHROPOIETIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; MELPHALAN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; DENDRITIC CELL; DRUG MEGADOSE; EX VIVO STUDY; FEMALE GENITAL TRACT TUMOR; GENE THERAPY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; LEUKOPENIA; LYMPH NODE METASTASIS; LYMPHOCYTE TRANSFUSION; MEDICAL RESEARCH; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; ONCOLOGY; OVARY CANCER; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SOLID TUMOR; THROMBOCYTOPENIA; UMBILICAL CORD BLOOD; UTERINE CERVIX CANCER; VACCINATION;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CYTOKINES; FEMALE; GENITAL NEOPLASMS, FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS;

EID: 19944369790     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Peschle C, Botta R, Muller R, Valtieri M, Ziegler BL. Purification and functional assay of pluripotent stem cells. Rev Clin Exp Hematol 1993; 8: 3-14.
2. Bhatia M, Bonnet D, Murdoch B, Gan OI, Dick JE. A newly discovered class of human hemopoietic cells with SCID-repopulating activity. Nat Med 1998; 9: 1038-1045.
3. Almeida-Porada G, Porada C, Zanjani ED. Adult stem cell plasticity and methods of detection. Rev Clin Exp Hematol 2001; 5: 26-41.
4. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1999; 49: 8-31.
5. Hanai A. Trends and differentials in ovarian cancer: incidence, mortality and survival experience. APMIS (Suppl) 1990; 12: 1-20.
6. Ozols RF, Rubin SC, Thomas GM, Robboy S. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and practice of gynecologic oncology. Philadelphia: Lippincott, Williams and Wilkins; 2000.
7. Brun JL, Feyler A, Chene G, Saurel J, Brun G, Hocke C. Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 2000; 78: 21-27.
8. Skipper HE. Dose intensity versus total dose of chemotherapy: an experimental basis. In: De Vita V, Hellman S, Rosemberg SA, eds. Important advances in oncology. JB Lippincott; 1990.
9. Gore M, Mainwaring P, A'Hern R, et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol 1998; 16: 2426-2434.
10. Vriesendorp R, Aalders JG, Sleijfer DT, et al. Effective high-dose chemotherapy with autologous bone marrow infusion in resistant ovarian cancer. Gynecol Oncol 1984; 17: 271-276.
11. Christian MC, Trimble EL. Salvage chemotherapy for epithelial ovarian carcinoma. Gynecol Oncol 1994; 55(3 Suppl): 143-150.
12. Stiff PJ, Bayer R, Kerger C, et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate anlysis of survival for 100 consecutive treated patients. J Clin Oncol 1997; 5: 1309-1317.
13. Janssen WE. Peripheral blood and bone marrow hematopoietic stem cells: are they the same? Semin Oncol 1993; 20 (6 Suppl): 19-27.
14. Aghajanian C, Fennelly D, Shapiro F, et al. Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer. J Clin Oncol 1998; 16: 1852-1860.
15. Schilder R, Brady MF, Spriggs D, Shea T. Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer. Gynecol Oncol 2003; 88: 3-8.
16. Legros M, Dauplat S, Fleury J, et al. High-dose chemotherapy with hematopoietc rescue in patients with stage III to IV ovarian cancer: long-term results. J Clin Oncol 1997; 15: 1302-1308.
17. Bertucci F, Viens P, Gravis G, et al. High dose chemotherapy with hematopoietic stem cell support in patients with advanced epithelial ovarian cancer: analysis of 67 patients treated in a single institution. Anticancer Res 1999; 19: 1455-1462.
18. Stiff PJ, Shpall EJ, Liu PY, et al. Randomized phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group Study. Gynecol Oncol 2004; 94: 98-106.
19. Donato ML, Aleman A, Champlin RE, et al. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 2004; 33: 1219:1224.
20. Curè H, Battista C, Guastalla J, et al. Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with advanced ovarian cancer (AOC): 5-year follow-up of a GINECO/FNCLCC/SFGM-TC study. Proc Am Soc Clin Oncol 2004; abstr.5006.
21. Salerno MG, Ferrandina G, Greggi S, et al. High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: long-term results. Bone Marrow Transplant 2001; 27: 1017-1025.
22. Ferrandina G, Perillo A, Pierelli L, et al. Carboplatin-based neoadjuvant treatment with peripheral blood stem cell and growth factor support in locally advanced cervical cancer patients with bulky metastatic lymph nodes. Int J Gynecol Cancer (submitted).
23. Ganser A, Bergmann M, Volkers B, et al. In vivo effects of recombinant human erythropoietin on circulating human hematopoietic progenitor cells. Exp Hematol 1989; 17: 433-435.
24. Kessinger A, Bishop M, Jackson JD, et al. Erythropietin for mobilization of circulating progenitor cells in patients with previously treated relapsed malignancies. Exp Hematol 1995; 23: 609-612.
25. Kurzrock R, Talpaz M, Gutterman JU, et al. Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia. Am J Med 1992; 93: 41-48.
26. Pierelli L, Scambia G, Menichella G, et al. The combination of erytrhropoietin and granulocyte colony stimulating factor increases the rate of haematopoietic recovery with clinical benefit after peripheral blood progenitor cell transplantation. Br J Haematol 1996; 96: 287-294.
27. Pierelli L, Perillo A, Greggi S, et al. Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison. J Clin Oncol 1999; 17: 1288-1295.
28. Perillo A, Pierelli L, Scambia G, et al. Peripheral blood progenitor cell collection after epirubicin, paclitaxel and cisplatin combination chemotherapy using erythropoietin-based cytokine regimens: a randomized comparison of G-CSF versus sequential GM-/G-CSF. Transfusion 2001; 41: 674-680.
29. Perillo A, Ferrandina G, Pierelli L, Rutella S, Mancuso S, Scambia G. Cytokines alone for PBPC collection in patients with advanced gynaecological malignancies: G-CSF vs G-CSF plus EPO. Bone Marrow Transplant 2004; 34: 743-744.
30. Guillaume T, Rubinstein DB, and Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 1998; 92: 1471-1490.
31. Nieto Y, Shpall EJ, McNiece IK, et al. Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant. Clin Cancer Res 2004; 10: 5076-5086.
32. Pierelli L, Perillo A, Ferrandina G, et al. The role of growth factor administration and T-cell recovery after peripheral blood progenitor cell transplantation in the treatment of solid tumors: results from a randomized comparison of G-CSF and GM-CSF. Transfusion 2001; 41: 1577-1585.
33. Perillo A, Pierelli L, Battaglia A, et al. Administration of low-dose interleukin-2 plus G-CSF/EPO early after autologous PBSC transplantation: effects on immune recovery and NK activity in a prospective study in women with breast and ovarian cancer. Bone Marrow Transplant 2002; 30: 571-578.
34. Ferrandina G, Pierelli L, Perillo A, et al. Lymphocyte recovery in advanced ovarian cancer patients after high-dose chemotherapy and peripheral blood stem cell plus growth factor support: clinical implications. Clin Cancer Res 2003; 9: 195-200.
35. Gilboa E, Nair SK, Lyerly HK. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 1998; 46: 82-87.
36. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cell. Nat Med 1996; 2: 52-58.
37. Schuler G, Steinman RM. Dendritic cells as adjuvants for immune-mediated resistance to tumours. J Exp Med 1997; 186:1183-1187.
38. Santin AD, Bellone S, Underwood LJ, et al. Novel immunotherapeutic strategies in gynaecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer. Minerva Ginecol 2002; 54:133-144.
39. Lemoli RM, Curti A, Fogli M, Ferri E, Baccarani M. The therapeutic role of dendritic cells in cancer immuotherapy. Haematologica 2002; 87 (8 Suppl): 62-66.
40. Ioannides CG, Fisk B, Pollack MS, Frazier ML, Taylor Wharton J, Freedman RS. Cytotoxic T-cell clones isolated from ovarian tumour infiltrating lymphocytes recognize common determinants on non ovarian tumour clones. Scand J Immunol 1993; 37: 413-424.
41. Flinn OJ, Jerome KR, Henderson RA, et al. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 1995; 145: 61-89.
42. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogenic blood progenitor-cell tranplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 8: 2817-2824.
43. Ueno N, Rondon G, Mirza NQ, et al. Allogenic peripheral-blood progenitor-cell transplantation for poor risk patients with metastatic breast cancer. J Clin Oncol 1998; 16: 986-993.
44. Bay JO, Choufi B, Pomel C, et al. Potential allogenic graft-versus-tumor effect in a patient with ovarian cancer. Bone Marrow Transplant 2000; 25: 681-682.
45. Giralt S, Khouri I, Champlin R. Non myeloablative "mini transplants". Cancer Treat Res 1999; 101: 97-108.
46. Kolb HJ, Schattemberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
47. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogenic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-758.
48. Makimoto A, Mineishi S, Tanosaki R, et al. Non-myeloablative stem cell transplantation (NST) for refractory solid tumors. Proc Am Soc Clin Oncol 2001; abstr.44.
49. Pedrazzoli P, Da Prada GA, Giorgiani G, et al. Allogenic blood stem cell transplantation after a reduced-intensity, preparative regimen. A pilot study in patients with refractory malignancies. Cancer 2002; 94: 2409-2415.
50. Bregni M, Dodero A, Peccatori J, et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99: 4234-4236.
51. Bay JO, Fleury J, Choufi B, et al. Allogenic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. Bone Marrow Transplant 2002: 30: 95-102.
52. Hanel M, Bornhauser M, Muller J, Thiede C, Ehninger G, Kroschinsky F. Evidence for a graft-versus-tumor effect in refractory ovarian cancer. J Cancer Res Clin Oncol 2003; 129: 12-16.
53. Peccatori J, Bernardi M, Corti C, et al. Graft-versus-tumor effect following reduced-intensity allogenic stem cell transplantation in ovarian cancer. Proc Am Soc Clin Oncol 2003; abstr.3354.
54. Donato ML, Levenback C, Gershenson DM, McMeekin S, and Champlin R. Matched unrelated donor bone marrow transplantation for the treatment of platinum refractory ovarian carcinoma: a case report. Gynecol Oncol 2004; 92: 365-367.
55. Urbano-Ispizua A, Schmitz N, de Witte T, et al. Allogenic and autologous transplantation for hematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2002; 29: 639-646.
56. Hesdorffer C, Ayello J, Ward M, et al. Phase I trial of retroviral-mediated gene transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 1998; 16: 165-172.
57. Abonour R, Williams DA, Einhorn L, et al. Efficient retrovirus-mediated transfer of multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med 2000; 6: 652-658.
58. McNiece I, Jones R, Bearman S, et al. Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery in breast cancer patients following high-dose chemotherapy. Blood 2000; 36: 3001-3007
59. Rizzieri DA, Long GD, Vredenburgh JJ, et al. Successful allogenic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen. Blood 2001; 98: 3486-3488.
60. de Wynter EA, Testa NG. Interest of cord blood stem cells. Biomed Pharmacother 2001; 55: 195-200.
61. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003; 3: 895-902.
62. Al-Hajj M, Clarke M. Self-renewal and solid tumor stem cells. Oncogene 2004; 23: 7274-7282.
63. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
64. Smalley M, Ashworth A. Stem cells and breast cancer: a field in transit. Nat Rev Cancer 2003; 3: 832-844.
65. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004; 117: 3529-3545.
66. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-5828.
67. Singh SK, Clarke ID, Takuchiro H, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene 2004; 23: 7267-7273.
68. Hope KJ, Jin L, Dick JE. Acute myeloid leukaemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004; 5: 738-743.
69. Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke M. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 2004; 14: 43-47.